TERN
Terns Pharmaceuticals, Inc.
$52.95
+0.00%
2026-05-15
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Key Fundamentals
Forward P/E
-34.01
EPS (TTM)
$-1.03
ROE
-14.2%
Profit Margin
0.0%
Debt/Equity
0.09
Price/Book
5.91
Beta
-0.38
Market Cap
$6.12B
Avg Volume (10D)
2.4M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$53.19
60D Low
$37.37
Avg Volume
5.7M
Latest Close
$52.95
Get breakout alerts for TERN
Sign up for Breakout Scanner to receive daily notifications when TERN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Terns Pharmaceuticals, Inc. (TERN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors TERN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. TERN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.